KR20220157516A - 심혈관 위험을 감소시키는 방법 - Google Patents

심혈관 위험을 감소시키는 방법 Download PDF

Info

Publication number
KR20220157516A
KR20220157516A KR1020227039740A KR20227039740A KR20220157516A KR 20220157516 A KR20220157516 A KR 20220157516A KR 1020227039740 A KR1020227039740 A KR 1020227039740A KR 20227039740 A KR20227039740 A KR 20227039740A KR 20220157516 A KR20220157516 A KR 20220157516A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227039740A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 베삭
코린느 하노틴
로버트 씨. 포디
윌리엄 제이. 사시엘라
그레고리 지. 슈워츠
필립 가브리엘 스테그
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Priority to KR1020247040556A priority Critical patent/KR20250006995A/ko
Publication of KR20220157516A publication Critical patent/KR20220157516A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227039740A 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법 Ceased KR20220157516A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247040556A KR20250006995A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293 2015-02-26
EP15305293.1 2015-02-26
KR1020167028383A KR20160132459A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167028383A Division KR20160132459A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040556A Division KR20250006995A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법

Publications (1)

Publication Number Publication Date
KR20220157516A true KR20220157516A (ko) 2022-11-29

Family

ID=52648962

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227039740A Ceased KR20220157516A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법
KR1020247040556A Pending KR20250006995A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법
KR1020167028383A Ceased KR20160132459A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247040556A Pending KR20250006995A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법
KR1020167028383A Ceased KR20160132459A (ko) 2014-03-17 2015-03-13 심혈관 위험을 감소시키는 방법

Country Status (14)

Country Link
US (2) US20150284473A1 (cg-RX-API-DMAC7.html)
EP (2) EP3119810B1 (cg-RX-API-DMAC7.html)
JP (3) JP2017509624A (cg-RX-API-DMAC7.html)
KR (3) KR20220157516A (cg-RX-API-DMAC7.html)
CN (3) CN106794244A (cg-RX-API-DMAC7.html)
AU (3) AU2015231713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2942549A1 (cg-RX-API-DMAC7.html)
EA (1) EA039310B1 (cg-RX-API-DMAC7.html)
ES (1) ES2978990T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066839T2 (cg-RX-API-DMAC7.html)
IL (1) IL304491A (cg-RX-API-DMAC7.html)
MX (1) MX380767B (cg-RX-API-DMAC7.html)
PL (1) PL3119810T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015142668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA3129996C (en) 2009-06-15 2025-09-02 Amarin Pharmaceuticals Ireland Limited COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
EP3753575A1 (en) * 2014-07-16 2020-12-23 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9
KR20240017117A (ko) 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016046684A1 (en) 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
TW202521589A (zh) * 2018-03-06 2025-06-01 法商賽諾菲生物技術公司 降低心血管風險的方法
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
TN2021000028A1 (en) * 2018-08-17 2022-10-03 Amarin Pharmaceuticals Ie Ltd Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
DK4056176T3 (da) 2018-09-24 2024-05-06 Amarin Pharmaceuticals Ie Ltd Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CA3192235A1 (en) * 2019-11-07 2021-05-14 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
WO2021097120A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20230312750A1 (en) * 2019-11-18 2023-10-05 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR084938A1 (es) * 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Also Published As

Publication number Publication date
KR20250006995A (ko) 2025-01-13
AU2021201118A1 (en) 2021-03-11
ES2978990T3 (es) 2024-09-23
AU2015231713B2 (en) 2020-11-19
JP2024147744A (ja) 2024-10-16
JP2017509624A (ja) 2017-04-06
KR20160132459A (ko) 2016-11-18
EP4403213A2 (en) 2024-07-24
US20220144969A1 (en) 2022-05-12
EP3119810B1 (en) 2024-02-28
EP3119810A1 (en) 2017-01-25
EA201691847A1 (ru) 2017-01-30
EP4403213A3 (en) 2024-10-23
JP2022141868A (ja) 2022-09-29
CA2942549A1 (en) 2015-09-24
PL3119810T3 (pl) 2024-07-15
AU2024205254A1 (en) 2024-10-03
CN106794244A (zh) 2017-05-31
EP3119810C0 (en) 2024-02-28
IL304491A (en) 2023-09-01
EA039310B1 (ru) 2022-01-12
US20150284473A1 (en) 2015-10-08
CN114558129A (zh) 2022-05-31
HUE066839T2 (hu) 2024-09-28
WO2015142668A1 (en) 2015-09-24
CN114642661A (zh) 2022-06-21
AU2015231713A1 (en) 2016-10-20
MX380767B (es) 2025-03-12
MX2016011975A (es) 2016-12-05

Similar Documents

Publication Publication Date Title
US20220144969A1 (en) Methods for reducing cardiovascular risk
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
JP6994484B2 (ja) 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
KR102482375B1 (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
US11904017B2 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
HK1232890B (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221114

Application number text: 1020167028383

Filing date: 20161012

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230126

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240104

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240708

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D